VIR BIOTECHNOLOGY INC. - COMMON STOCK

Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

08 Mar 2023 15:05:07 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

28 Feb 2023 15:05:38 By Nasdaq GlobeNewswire

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

23 Feb 2023 15:05:01 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)

22 Feb 2023 07:30:38 By Nasdaq GlobeNewswire

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

16 Feb 2023 15:05:13 By Nasdaq GlobeNewswire

Vir Biotechnology Appoints Sung Lee as Chief Financial Officer

16 Feb 2023 07:30:01 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Amended Collaboration Agreement with GSK

13 Feb 2023 15:45:02 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor

25 Jan 2023 07:29:00 By Nasdaq GlobeNewswire

Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A

21 Dec 2022 07:00:17 By Nasdaq GlobeNewswire

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

16 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection

06 Nov 2022 09:35:00 By Nasdaq GlobeNewswire

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

03 Nov 2022 15:03:00 By Nasdaq GlobeNewswire

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022

31 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022

28 Oct 2022 17:06:18 By Nasdaq GlobeNewswire

Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A

18 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

11 Oct 2022 15:03:00 By Nasdaq GlobeNewswire

Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats

04 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection

22 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 15:05:00 By Nasdaq GlobeNewswire